Study S002737

Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

ClinicalTrials.gov record

Registration

Registration: NCT07311850
Acronym: VESPER-4
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 3578
Start: 2025-12-19
Primary completion: 2027-09-21
Lead sponsor: Pfizer
Conditions: Obesity and Overweight
Interventions: DRUG:MET097; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:C6491007; REGISTRY:2025-523974-18-00; OTHER:VESPER-4; NIH:2025

Registered primary outcomes

Percent change from baseline in body weight [Baseline (Day 0) to Week 64]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.